MODERNA INC

Moderna insider buy‑plan by President Dr. Hoge reveals disciplined buying just before a 34% rally, hinting at confidence in the company’s expanding vaccine pipeline.

Moderna’s legal chief’s disciplined 10b5‑1 buys show insider confidence as the mRNA‑driven stock climbs—a bullish signal for investors watching the company’s expanding portfolio.

Moderna CFO James Mock buys 2,475 shares, reinforcing insider confidence in the biotech’s mRNA growth and signaling steady executive support amid active trading.

Moderna insiders’ massive option and RSU grants signal bullish confidence amid soaring mRNA vaccine momentum and a 111% year‑to‑date surge, boosting investor optimism for future growth.

Moderna insider buying surge: Sandra Horning’s 16,233‑share purchase signals bullish confidence in the company’s mRNA pipeline and revenue growth.

Moderna insider trades reveal a steady, long‑term buy‑hold stance, with executive purchases reflecting confidence in the mRNA platform and a bullish outlook.

Moderna’s chief legal officer buys shares after a $2.25 billion patent settlement—showing executive confidence and a clearer IP path for future mRNA growth.

Moderna CEO Stéphane Bancel’s March 1, 2026 buy of 250,932 shares signals steady insider confidence amid a mRNA rally and upcoming approvals.

Moderna CFO’s 2026 stock sale shows routine tax‑liquidation, not a sell‑off, underscoring insider moves as context rather than market signals.

Moderna CEO Stéphane Bancel’s recent PSU vesting boosts his stake by ~2 %—a bullish sign of leadership confidence amid regulatory setbacks and future mRNA pipeline growth.